A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Megan L Ryan;  ; Daniel E Falk; Joanne B Fertig; Beatrice Rendenbach-Mueller; David A Katz; Katherine A Tracy; Eric C Strain; Kelly E Dunn; Kyle Kampman; Elizabeth Mahoney; Domenic A Ciraulo; Laurie Sickles-Colaneri; Nassima Ait-Daoud; Bankole A Johnson; Janet Ransom; Charles Scott; George F Koob; Raye Z Litten

doi:10.1038/npp.2016.214

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Neuropsychopharmacology ◽

10.1038/npp.2016.214 ◽

2016 ◽

Vol 42 (5) ◽

pp. 1012-1023 ◽

Cited By ~ 33

Author(s):

Megan L Ryan ◽

◽

Daniel E Falk ◽

Joanne B Fertig ◽

Beatrice Rendenbach-Mueller ◽

...

Keyword(s):

Alcohol Dependence ◽

Randomized Trial ◽

Receptor Antagonist ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

V1b Receptor

Download Full-text

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793503497 ◽

2015 ◽

Author(s):

Brendan J Canning

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Active Rheumatoid Arthritis ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

Download Full-text

AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.5174 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 1119.2-1119 ◽

Cited By ~ 2

Author(s):

P. Gordon ◽

R. Cooper ◽

H. Chinoy ◽

D. Isenberg ◽

I.E. Lundberg ◽

...

Keyword(s):

Clinical Trial ◽

Receptor Antagonist ◽

Phase 2 ◽

Toll Like Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Clinical Trial

Download Full-text

Faculty Opinions recommendation of EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718270683.793501691 ◽

2014 ◽

Author(s):

Nanna Finnerup

Keyword(s):

Clinical Trial ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Postherpetic Neuralgia ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Novel Treatment ◽

Phase 2 Clinical Trial

Download Full-text

Daridorexant (Act-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder: a randomized, double-blind, placebo-controlled, active-reference phase 2 study

Sleep Medicine ◽

10.1016/j.sleep.2019.11.232 ◽

2019 ◽

Vol 64 ◽

pp. S85

Author(s):

Y. Dauvilliers ◽

G. Zammit ◽

I. Fietze ◽

D. Mayleben ◽

D. Sebök Kinter ◽

...

Keyword(s):

Receptor Antagonist ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Insomnia Disorder ◽

Phase 2 Study ◽

Reference Phase

Download Full-text

Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Journal of Psychiatric Research ◽

10.1016/j.jpsychires.2020.05.017 ◽

2020 ◽

Vol 128 ◽

pp. 43-51

Author(s):

Makoto Kamiya ◽

Helene D. Sabia ◽

Julie Marella ◽

Maurizio Fava ◽

Charles B. Nemeroff ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Receptor Antagonist ◽

Adjunctive Treatment ◽

Controlled Study ◽

Efficacy And Safety ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo ◽

V1b Receptor

Download Full-text

Daridorexant (ACT-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder in the elderly: results from a randomized, double-blind, placebo-controlled, 5-period, 5-treatment crossover dose-response phase 2 study

Sleep Medicine ◽

10.1016/j.sleep.2019.11.1228 ◽

2019 ◽

Vol 64 ◽

pp. S437-S438

Author(s):

G. Zammit ◽

Y. Dauvilliers ◽

S. Pain ◽

D. Sebök Kinter ◽

D. Kunz

Keyword(s):

Receptor Antagonist ◽

Dose Response ◽

The Elderly ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Insomnia Disorder ◽

Phase 2 Study ◽

Response Phase

Download Full-text

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study

The Lancet ◽

10.1016/s0140-6736(14)61255-1 ◽

2015 ◽

Vol 385 (9974) ◽

pp. 1198-1205 ◽

Cited By ~ 232

Author(s):

Rayid Abdulqawi ◽

Rachel Dockry ◽

Kimberley Holt ◽

Gary Layton ◽

Bruce G McCarthy ◽

...

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial

The Lancet ◽

10.1016/s0140-6736(13)62337-5 ◽

2014 ◽

Vol 383 (9929) ◽

pp. 1637-1647 ◽

Cited By ~ 109

Author(s):

Andrew S C Rice ◽

Robert H Dworkin ◽

Tom D McCarthy ◽

Praveen Anand ◽

Chas Bountra ◽

...

Keyword(s):

Clinical Trial ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Postherpetic Neuralgia ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Novel Treatment ◽

Phase 2 Clinical Trial

Download Full-text

0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study

SLEEP ◽

10.1093/sleep/zsz067.374 ◽

2019 ◽

Vol 42 (Supplement_1) ◽

pp. A152-A153 ◽

Cited By ~ 1

Author(s):

Yves Dauvilliers ◽

Gary Zammit ◽

Ingo Fietze ◽

David Mayleben ◽

Dalma Seboek Kinter ◽

...

Keyword(s):

Receptor Antagonist ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Reference Phase

Download Full-text